Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-25-080015
Filing Date
2025-06-02
Accepted
2025-06-02 07:00:27
Documents
31
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 6-K imab_investor_present_06.htm 6-K 26561
2 EX-99.1 imab-ex99_1.htm EX-99.1 42974
3 GRAPHIC imab-ex99_1s1.jpg GRAPHIC 189050
4 GRAPHIC imab-ex99_1s2.jpg GRAPHIC 984575
5 GRAPHIC imab-ex99_1s3.jpg GRAPHIC 541071
6 GRAPHIC imab-ex99_1s4.jpg GRAPHIC 329447
7 GRAPHIC imab-ex99_1s5.jpg GRAPHIC 454668
8 GRAPHIC imab-ex99_1s6.jpg GRAPHIC 412515
9 GRAPHIC imab-ex99_1s7.jpg GRAPHIC 409769
10 GRAPHIC imab-ex99_1s8.jpg GRAPHIC 313710
11 GRAPHIC imab-ex99_1s9.jpg GRAPHIC 384797
12 GRAPHIC imab-ex99_1s10.jpg GRAPHIC 404407
13 GRAPHIC imab-ex99_1s11.jpg GRAPHIC 446577
14 GRAPHIC imab-ex99_1s12.jpg GRAPHIC 439286
15 GRAPHIC imab-ex99_1s13.jpg GRAPHIC 360770
16 GRAPHIC imab-ex99_1s14.jpg GRAPHIC 507616
17 GRAPHIC imab-ex99_1s15.jpg GRAPHIC 409284
18 GRAPHIC imab-ex99_1s16.jpg GRAPHIC 314971
19 GRAPHIC imab-ex99_1s17.jpg GRAPHIC 331502
20 GRAPHIC imab-ex99_1s18.jpg GRAPHIC 269278
21 GRAPHIC imab-ex99_1s19.jpg GRAPHIC 277045
22 GRAPHIC imab-ex99_1s20.jpg GRAPHIC 298627
23 GRAPHIC imab-ex99_1s21.jpg GRAPHIC 423505
24 GRAPHIC imab-ex99_1s22.jpg GRAPHIC 387297
25 GRAPHIC imab-ex99_1s23.jpg GRAPHIC 359008
26 GRAPHIC imab-ex99_1s24.jpg GRAPHIC 263985
27 GRAPHIC imab-ex99_1s25.jpg GRAPHIC 436362
28 GRAPHIC imab-ex99_1s26.jpg GRAPHIC 304634
29 GRAPHIC imab-ex99_1s27.jpg GRAPHIC 385646
30 GRAPHIC imab-ex99_1s28.jpg GRAPHIC 410035
31 GRAPHIC imab-ex99_1s29.jpg GRAPHIC 198776
  Complete submission text file 0000950170-25-080015.txt   15558205
Mailing Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850
Business Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850 (301) 670 2800
I-Mab (Filer) CIK: 0001778016 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39173 | Film No.: 251013104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)